Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome

Key Points Cardiovascular–kidney–metabolic (CKM) syndrome stages 1–4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults. Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation. CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality. Background It is imperative to critically evaluate the prognostic implications of cardiovascular–kidney–metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period. Methods This was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999–2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula. Results Over a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months. Conclusions Our findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2025-02-11
DOI
https://doi.org/10.1681/asn.0000000637
Citations
45
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
64.38
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome

Insa Marie Schmidt, Sophie E. Claudel, Sushrut S. Waikar, Ashish Verma
45 citations
Journal of the American Society of Nephrology
Chronic Kidney Disease and Diabetes
64.38
article

Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome

Insa Marie Schmidt, Sophie E. Claudel, Sushrut S. Waikar, Ashish Verma
article en
45 citations

Abstract

Key Points Cardiovascular–kidney–metabolic (CKM) syndrome stages 1–4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults. Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation. CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality. Background It is imperative to critically evaluate the prognostic implications of cardiovascular–kidney–metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period. Methods This was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999–2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula. Results Over a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months. Conclusions Our findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.

Journal of the American Society of NephrologyVol. 36(7)
Boston University (US), Boston Medical Center (US)
Good health and well-being
Openalex Percentile: Top 0%
Chronic Kidney Disease and Diabetes
64.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.